These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 17014391)

  • 1. Preclinical formulations for discovery and toxicology: physicochemical challenges.
    Neervannan S
    Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):715-31. PubMed ID: 17014391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing early formulations: practice and perspective.
    Li P; Zhao L
    Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated early formulation strategy--from hit evaluation to preclinical candidate profiling.
    Maas J; Kamm W; Hauck G
    Eur J Pharm Biopharm; 2007 Apr; 66(1):1-10. PubMed ID: 17123801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical vehicle use in studies by multiple routes in multiple species.
    Gad SC; Cassidy CD; Aubert N; Spainhour B; Robbe H
    Int J Toxicol; 2006; 25(6):499-521. PubMed ID: 17132609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
    Kramer JA; Sagartz JE; Morris DL
    Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragments, network biology and designing multiple ligands.
    Morphy R; Rankovic Z
    Drug Discov Today; 2007 Feb; 12(3-4):156-60. PubMed ID: 17275736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and novel strategies in pre-clinical formulation development: an overview.
    Shah AK; Agnihotri SA
    J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 14. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species.
    Wuelfing WP; Daublain P; Kesisoglou F; Templeton A; McGregor C
    Mol Pharm; 2015 Apr; 12(4):1031-9. PubMed ID: 25671350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical excipient development: the need for preclinical guidance.
    Baldrick P
    Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical testing for teratogenicity and developmental toxicity: methods and limitations.
    Barrow PC
    Therapie; 2002; 57(2):109-14. PubMed ID: 12185956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for bringing drug delivery tools into discovery.
    Kwong E; Higgins J; Templeton AC
    Int J Pharm; 2011 Jun; 412(1-2):1-7. PubMed ID: 21421040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Snapshot PK: a rapid rodent in vivo preclinical screening approach.
    Liu B; Chang J; Gordon WP; Isbell J; Zhou Y; Tuntland T
    Drug Discov Today; 2008 Apr; 13(7-8):360-7. PubMed ID: 18405850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
    Pouton CW; Porter CJ
    Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.